Document is current
Any future updates will be listed below
-
Authors
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Mateos, María-Victoria https://orcid.org/0000-0003-2390-1218
Schaeffer, Marcy
Lin, Xiwu
Bathija, Sacheeta
Gupta-Werner, Niodita
Lam, Annette
Carson, Robin
Dennis, Robyn
Kaila, Shuchita
Matt, Kathryn
Duran, Joana
Lonial, Sagar https://orcid.org/0000-0002-8322-9323
-
Funding
Funding for this research was provided by:
Janssen Research and Development & Development, LLC
- License Information
-
More Information
Article History
Received: 29 March 2024
Revised: 15 August 2024
Accepted: 14 October 2024
First Online: 5 December 2024
Competing interests
: S. Vincent Rajkumar is co-editor of <i>Blood Cancer Journal</i> but did not participate in the processing or review of this manuscript. María-Victoria Mateos has served in a consulting or advisory role for Amgen, AbbVie, Celgene, Janssen-Cilag, GlaxoSmithKline, Pfizer, Regeneron, Roche-Genentech, and Takeda, and received honoraria from Amgen, AbbVie, Celgene, GlaxoSmithKline, Genentech, Janssen-Cilag, Sanofi, and Takeda. Marcy Schaeffer, Xiwu Lin, Sacheeta Bathija, Niodita Gupta-Werner, Annette Lam, Robin Carson, Robyn Dennis, Shuchita Kaila, Kathryn Matt, and Joana Duran are employees of Janssen. Sagar Lonial has served in a consulting or advisory role for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen Oncology, Juno Therapeutics, Merck Novartis, and Takeda.
: Not applicable as this study was a retrospective, observational study, which leveraged data from the Flatiron Health database. This nationwide oncology practices registry includes deidentified patient data from electronic health records from ~280 cancer clinics in the United States and has been used extensively to generate real-world evidence on various cancers, including multiple myeloma.
